Why Innovus Pharma?

Manufactured in an NSF-Registered Facility
Under GMP

The facility where UriVarx™ and other Innovus Pharma nutritional supplements are manufactured is registered with NSF and is in compliance with current Good Manufacturing Practices (cGMPs). These guidelines define the manufacturing processes, procedures, and documentation that assure the identity, strength, composition, and quality of the product.

Medical & Clinical Advisory Boards Oversight

The leading US and International academic/clinical physicians, Key Opinion Leaders and scientists of Innovus Pharma Medical and Clinical Advisory Boards meet to oversee the clinical trials, research and all product formulations. We are continuously monitoring responses and any side effect by customers to address and improve our formulations.

For more information on our Medical and Clinical Advisory Boards please visit our corporate website at www.innovuspharma.com
**UriVarx™**

**UriVarx™** is a dietary supplement composed of a proprietary patented blend of synergistic herbs designed to:

- Promote and support healthy bladder function*
- Help reduce frequency*
- Maintain control*

**Suggested Use**

Take two (2) capsules daily with meals or as instructed by a healthcare professional.

**Supplement Facts**

<table>
<thead>
<tr>
<th>Serving Size 2 capsules</th>
<th>Servings per container 30</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Amount Per Serving</th>
<th>% DV</th>
</tr>
</thead>
<tbody>
<tr>
<td>UriVarx™ proprietary blend</td>
<td>840mg</td>
</tr>
<tr>
<td>Lindera (Lindera aggregata) extract (root)</td>
<td></td>
</tr>
<tr>
<td>Horsetail (Equisetum arvense) extract (aerial parts)</td>
<td></td>
</tr>
<tr>
<td>Cratevox™ Three-leaf Caper (Crateva nurvala) extract (bark)</td>
<td></td>
</tr>
</tbody>
</table>

- Daily Value (DV) not established.

Other Ingredients: Vegetable capsule (HPMC, water), rice flour and silica.

**Dosage Size**

Each serving contains 840 mg of UriVarx™ proprietary blend.

**Warnings and Precautions**

Consult a physician before using if pregnant, nursing or on medication.
DESCRIPTION

UriVarx™ is a proprietary blend of the following botanical ingredients

Lindera (Lindera aggregata) extract
Horsetail (Equistum arvense) extract (aerial parts)
Cratevox™ Three -leaf caper (Cratexa nurvala) extract (bark)

Additional ingredients are vegetable capsule (HPMC, water), rice flour and silica.

Linder extract (Lindera aggregate) is a root that has been used to support healthy urinary and kidney function.*

Horsetail extract (Equisetum arvense) is a plant listed on the German Commission E monograph to support and maintain the health of the urinary tract.*

Cratevox™ Three -leaf caper extract (Cratexa nurvala) bark demonstrated in pre-clinical studies to enhance bladder tone. In an uncontrolled clinical study, Cratexa nurvala bark supported healthy urinary function and bladder tone after 3 months of use.*

ADVERSE REACTIONS

UriVarx™ has been shown to be well tolerated.

USE IN SPECIFIC POPULATIONS

Pregnancy: UriVarx™ has not been studied for effect during use while pregnant. As with any dietary supplement, consult a physician before using if pregnant, nursing or on medication.

CLINICAL RESEARCH ON URIVARX™

UriVarx™ was evaluated in two clinical studies. The first study compared the efficacy of crateva, horsetail and mineral combination compared to UriVarx™. Comparison was made using the percent (%) reduction in frequency and urination and nocturia for each of the treatment groups at months one and three. Following one month of use, UriVarx™ was more effective in reducing the frequency of day urination (Figure 1) and superior in reducing nocturnia (Figure 2) compared to crateva and horsetail alone.
UriVarx™ was evaluated in an 8-week, double-blind, randomized, placebo-controlled, clinical study conducted at two sites. UriVarx™ was assessed in 142 subjects (81 female and 61 male) on urinary frequency and urgency. Data was collected at 2, 4, and 8 weeks. The primary outcome measure was self-reported urinary frequency defined as the number of voluntary diurnal and/or nocturnal micturitions. Baseline reported measurements were similar between groups. At week 8, mean (n/day) urinary day frequency was significantly lower in subjects administered UriVarx™ compared to placebo (Figure 3). Similarly, mean episodes of nocturia and urgency were significantly fewer versus placebo (Figures 4 & 5). Significant improvements in quality of life were reported at end of study in comparison to placebo.

There were no adverse events leading to discontinuation. Five episodes of transient adverse reactions were reported in the UriVarx™ group which included diarrhea (2.9%), UTI (2.9%) and flatulence (1.5%).

**HOW SUPPLIED/STORAGE AND HANDLING**

UriVarx™ is supplied as an oval vegetable capsule, available in bottles containing 60 capsules.
Store in a cool dry place at room temperature.

Urivarx™ is a dietary supplement and not a drug. It is not indicated for overactive bladder (OAB) or any other medical condition, disease or disorder.

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

MANUFACTURED IN THE UNITED STATES

Marketed and Distributed by:

**Innovus Pharmaceuticals, Inc.**

San Diego, CA 92122

Urivarx™ is a registered trademark of Innovus Pharmaceuticals, Inc. Cratevox™ is a registered trademark of Seipel Group P/L. All other trademarks or registered trademarks are the property of their respective owners.

©2016 Innovus Pharmaceuticals, Inc.

Revised October 2016